Skip to main content

Compare Stocks

Date Range: 

 Concert PharmaceuticalsAcelRx PharmaceuticalsOnconova TherapeuticsNeuBase TherapeuticsActinium Pharmaceuticals
SymbolNASDAQ:CNCENASDAQ:ACRXNASDAQ:ONTXNASDAQ:NBSENYSEAMERICAN:ATNM
Price Information
Current Price$3.95$1.16$0.53$5.08$7.09
52 Week RangeBuySellHoldBuyBuy
MarketRank™
Overall Score1.80.81.51.51.5
Analysis Score3.50.53.13.53.5
Community Score2.72.72.73.03.2
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.80.0
Earnings & Valuation Score1.30.60.00.00.6
Analyst Ratings
Consensus RecommendationBuySellHoldBuyBuy
Consensus Price Target$19.25$0.84$1.52$17.33$41.00
% Upside from Price Target387.34% upside-27.59% downside188.34% upside241.21% upside478.28% upside
Trade Information
Market Cap$127.09 million$138.16 million$124.46 million$117.75 million$136.45 million
Beta0.771.162.030.411.23
Average Volume440,3764,750,12338,720,574364,557340,348
Sales & Book Value
Annual Revenue$1.08 million$2.29 million$2.18 millionN/AN/A
Price / Sales117.6760.3357.09N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.26 per share($0.52) per share$0.08 per share$1.35 per share$1.03 per share
Price / Book0.93-2.236.58N/AN/A
Profitability
Net Income$-78,170,000.00$-53,240,000.00$-21,500,000.00$-17,390,000.00$-21,900,000.00
EPS($3.29)($0.67)($1.49)($0.89)N/A
Trailing P/E RatioN/AN/AN/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-921.38%-890.43%-11,997.55%N/AN/A
Return on Equity (ROE)-55.20%N/A-161.10%-90.43%-77.96%
Return on Assets (ROA)-44.83%-60.72%-89.69%-77.20%-64.62%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio18.51%2.89%2.69%10.42%10.51%
Quick Ratio18.51%2.77%2.69%10.42%10.51%
Ownership Information
Institutional Ownership Percentage69.68%24.45%6.67%28.98%17.55%
Insider Ownership Percentage10.10%8.10%1.80%24.00%1.50%
Miscellaneous
Employees7154111532
Shares Outstanding32.17 million119.10 million236.61 million23.18 million19.25 million
Next Earnings Date8/5/2021 (Estimated)5/17/2021 (Confirmed)5/17/2021 (Estimated)8/12/2021 (Estimated)8/13/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Actinium: Q1 Earnings SnapshotActinium: Q1 Earnings Snapshot
sfgate.com - May 14 at 7:48 PM
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Price Up 2.3%Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Price Up 2.3%
americanbankingnews.com - May 13 at 12:10 AM
Glenmark Pharma’s API arm files papers with Sebi to unlock value via IPOGlenmark Pharma’s API arm files papers with Sebi to unlock value via IPO
msn.com - April 17 at 7:55 AM
Global Healthcare API Market (2020 to 2025) - Featuring Apple, General Electric and Cerner Among Others - ResearchAndMarkets.comGlobal Healthcare API Market (2020 to 2025) - Featuring Apple, General Electric and Cerner Among Others - ResearchAndMarkets.com
ca.finance.yahoo.com - April 13 at 8:23 AM
Centre Prohibits Export Of Remdesivir & Its API Till COVID-19 Situation Improves In IndiaCentre Prohibits Export Of Remdesivir & Its API Till COVID-19 Situation Improves In India
republicworld.com - April 12 at 3:45 PM
Mumbai Police suspends Vaze’s former colleague API KaziMumbai Police suspends Vaze’s former colleague API Kazi
dailypioneer.com - April 12 at 3:45 PM
Antilia bomb scare case: API Kazi suspended a day after arrestAntilia bomb scare case: API Kazi suspended a day after arrest
freepressjournal.in - April 12 at 3:45 PM
Actinium Pharmaceuticals Inc (ATNM)Actinium Pharmaceuticals Inc (ATNM)
investing.com - April 12 at 12:13 AM
Novel Cancer Therapy Phase 3 Trial Expects To Be Completed ShortlyNovel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly
markets.businessinsider.com - April 6 at 11:36 AM
Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth PlansActinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - April 5 at 7:09 AM
Actinium to Participate in the Cell & Gene Meeting on the MediterraneanActinium to Participate in the Cell & Gene Meeting on the Mediterranean
finance.yahoo.com - March 31 at 6:48 PM
Actinium initiates patient enrollment in Iomab-ACT trial prior to CD19 CAR t-cell therapyActinium initiates patient enrollment in Iomab-ACT trial prior to CD19 CAR t-cell therapy
seekingalpha.com - March 26 at 12:36 AM
Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AMLActinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML
finance.yahoo.com - March 25 at 9:34 AM
Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell TherapyActinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy
finance.yahoo.com - March 24 at 7:58 AM
Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARCActinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC
finance.yahoo.com - March 11 at 7:37 AM
Actinium Announces Appointment of Mark Kubik, MBA as Chief Business OfficerActinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer
finance.yahoo.com - March 3 at 7:43 AM
Actinium Announces Participation in H.C. Wainwright Global Life Sciences ConferenceActinium Announces Participation in H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 9:11 AM
Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual MeetingActinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting
finance.yahoo.com - February 11 at 8:05 AM
Actinium Announces Participation in BIO CEO & Investor Digital ConferenceActinium Announces Participation in BIO CEO & Investor Digital Conference
finance.yahoo.com - February 10 at 7:37 AM
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Contineus To Thrive In 2021, As Its Stock Is Up 22.95% Year-To-DateActinium Pharmaceuticals, Inc. (NYSE:ATNM) Contineus To Thrive In 2021, As Its Stock Is Up 22.95% Year-To-Date
marketingsentinel.com - February 8 at 11:46 PM
Actinium Pharmaceuticals (ATNM) Resisting at $9, would it Surpass $10 any time soon?Actinium Pharmaceuticals (ATNM) Resisting at $9, would it Surpass $10 any time soon?
stockstelegraph.com - February 7 at 12:42 AM
Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor ConferenceActinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
finance.yahoo.com - January 20 at 8:15 AM
Actinium Pharma Announces Research Collaboration With Astellas - Quick FactsActinium Pharma Announces Research Collaboration With Astellas - Quick Facts
markets.businessinsider.com - January 13 at 8:01 AM
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted RadiotherapiesActinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
finance.yahoo.com - January 13 at 7:23 AM
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Actinium Pharmaceuticals (ATNM)Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Actinium Pharmaceuticals (ATNM)
smarteranalyst.com - December 29 at 12:28 PM
DateCompanyBrokerageAction
5/4/2021Concert PharmaceuticalsMizuhoReiterated Rating
2/2/2021Concert PharmaceuticalsTruistLower Price Target
2/2/2021Concert PharmaceuticalsHC WainwrightReiterated Rating
12/16/2020Concert PharmaceuticalsBerenberg BankInitiated Coverage
11/4/2020Concert PharmaceuticalsJMP SecuritiesInitiated Coverage
3/30/2020Concert PharmaceuticalsJefferies Financial GroupInitiated Coverage
2/27/2020Concert PharmaceuticalsStifel NicolausDowngrade
1/22/2020Concert PharmaceuticalsSunTrust BanksReiterated Rating
9/30/2019Concert PharmaceuticalsJanney Montgomery ScottReiterated Rating
8/13/2020AcelRx PharmaceuticalsCredit Suisse GroupBoost Price Target
5/12/2020AcelRx PharmaceuticalsLADENBURG THALM/SH SHReiterated Rating
4/24/2019AcelRx PharmaceuticalsB. RileyInitiated Coverage
1/29/2019AcelRx PharmaceuticalsCantor FitzgeraldSet Price Target
12/11/2018AcelRx PharmaceuticalsOppenheimerReiterated Rating
10/22/2018AcelRx PharmaceuticalsRoyal Bank of CanadaSet Price Target
12/22/2020Onconova TherapeuticsNoble FinancialUpgrade
11/13/2020Onconova TherapeuticsMaxim GroupReiterated Rating
8/24/2020Onconova TherapeuticsLaidlawDowngrade
8/14/2020NeuBase TherapeuticsChardan CapitalReiterated Rating
2/6/2020NeuBase TherapeuticsGuggenheimInitiated Coverage
9/24/2019NeuBase TherapeuticsBTIG ResearchInitiated Coverage
12/31/2020Actinium PharmaceuticalsWilliam BlairReiterated Rating
11/5/2020Actinium PharmaceuticalsAlliance Global PartnersInitiated Coverage
12/4/2018Actinium PharmaceuticalsRoth CapitalSet Price Target
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.